Alumis announced that patient dosing has commenced in the ONWARD Phase 3 clinical program. This Phase 3 program consists of two identical 24-week global Phase 3 clinical trials designed to evaluate the efficacy and safety of ESK-001 in adult patients with moderate-to-severe plaque psoriasis and includes a long-term extension trial, ONWARD3, that will evaluate durability and maintenance of response and long-term safety.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALMS:
- Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
- Under Armour downgraded, Snap upgraded: Wall Street’s top analyst calls
- Alumis initiated with an Overweight at Cantor Fitzgerald
- Alumis initiated with a Buy at Guggenheim on ESK-001 potential
- Alumis initiated with an Outperform at Leerink